Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 192

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Growth factors for treating diabetic foot ulcers

Open access
Martí-Carvajal, Arturo J, Gluud, Christian, Nicola, Susana, Simancas-Racines, Daniel, Reveiz, Ludovic, Oliva, Patricio, Cedeño-Taborda, Jorge·2015·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Foot ulcers are a major complication of diabetes mellitus, often leading to amputation. Growth factors derived from blood platelets, endothelium, or macrophages could potentially be an important treatment for these wounds but they may also confer risks. OBJECTIVES: To assess the benefits and harms of growth factors for foot ulcers in patients with type 1 or type 2 diabetes mellitus. SEARCH METHODS: In March 2015 we searched the Cochrane Wounds Group Specialised Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), Ovid MEDLINE, Ovid MEDLINE (In-Process & Other Non-Indexed Citations, Ovid EMBASE and EBSCO CINAHL. There were no restrictions with respect to language, date of publication or study setting. SELECTION CRITERIA: Randomised clinical trials in any setting, recruiting people with type 1 or type 2 diabetes mellitus diagnosed with a foot ulcer. Trials were eligible for inclusion if they compared a growth factor plus standard care (e.g., antibiotic therapy, debridement, wound dressings) versus placebo or no growth factor plus standard care, or compared different growth factors against each other. We considered lower limb amputation (minimum of one toe), complete healing of the foot ulcer, and time to complete healing of the diabetic foot ulcer as the primary outcomes. DATA COLLECTION AND ANALYSIS: Independently, we selected randomised clinical trials, assessed risk of bias, and extracted data in duplicate. We estimated risk ratios (RR) for dichotomous outcomes. We measured statistical heterogeneity using the I(2) statistic. We subjected our analyses to both fixed-effect and random-effects model analyses. MAIN RESULTS: We identified 28 randomised clinical trials involving 2365 participants. The cause of foot ulcer (neurologic, vascular, or combined) was poorly defined in all trials. The trials were conducted in ten countries. The trials assessed 11 growth factors in 30 comparisons: platelet-derived wound healing formula, autologous growth factor, allogeneic platelet-derived growth factor, transforming growth factor β2, arginine-glycine-aspartic acid peptide matrix, recombinant human platelet-derived growth factor (becaplermin), recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human vascular endothelial growth factor, recombinant human lactoferrin, and recombinant human acidic fibroblast growth factor. Topical intervention was the most frequent route of administration. All the trials were underpowered and had a high risk of bias. Pharmaceutical industry sponsored 50% of the trials.Any growth factor compared with placebo or no growth factor increased the number of participants with complete wound healing (345/657 (52.51%) versus 167/482 (34.64%); RR 1.51, 95% CI 1.31 to 1.73; I(2) = 51%, 12 trials; low quality evidence). The result is mainly based on platelet-derived wound healing formula (36/56 (64.28%) versus 7/27 (25.92%); RR 2.45, 95% 1.27 to 4.74; I(2) = 0%, two trials), and recombinant human platelet-derived growth factor (becaplermin) (205/428 (47.89%) versus 109/335 (32.53%); RR 1.47, 95% CI 1.23 to 1.76, I(2)= 74%, five trials).In terms of lower limb amputation (minimum of one toe), there was no clear evidence of a difference between any growth factor and placebo or no growth factor (19/150 (12.66%) versus 12/69 (17.39%); RR 0.74, 95% CI 0.39 to 1.39; I(2) = 0%, two trials; very low quality evidence). One trial involving 55 participants showed no clear evidence of a difference between recombinant human vascular endothelial growth factor and placebo in terms of ulcer-free days following treatment for diabetic foot ulcers (RR 0.64, 95% CI 0.14 to 2.94; P value 0.56, low quality of evidence)Although 11 trials reported time to complete healing of the foot ulcers in people with diabetes , meta-analysis was not possible for this outcome due to the unique comparisons within each trial, failure to report data, and high number of withdrawals. Data on quality of life were not reported. Growth factors showed an increasing risk of overall adverse event rate compared with compared with placebo or no growth factor (255/498 (51.20%) versus 169/332 (50.90%); RR 0.83; 95% CI 0.72 to 0.96; I(2) = 48%; eight trials; low quality evidence). Overall, safety data were poorly reported and adverse events may have been underestimated. AUTHORS' CONCLUSIONS: This Cochrane systematic review analysed a heterogeneous group of trials that assessed 11 different growth factors for diabetic foot ulcers. We found evidence suggesting that growth factors may increase the likelihood that people will have complete healing of foot ulcers in people with diabetes. However, this conclusion is based on randomised clinical trials with high risk of systematic errors (bias). Assessment of the quality of the available evidence (GRADE) showed that further trials investigating the effect of growth factors are needed before firm conclusions c

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008548.pub2

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 151

  1. Afshari, 2005, Efficacy of topical epidermal growth factor in healing diabetic foot ulcers, Therapy, 2, 759, 10.2217/14750708.2.5.759 · doi:10.2217/14750708.2.5.759
  2. Agrawal, 2009, Use of a platelet-derived growth factor gel in chronic diabetic foot ulcers, Diabetic Foot Journal, 12, 80
  3. Bhansali, 2009, Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?, Diabetes Research and Clinical Practice, 83, e13, 10.1016/j.diabres.2008.10.005 · DOI
  4. Chen, 2004, Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot, Modern Nursing, 10, 274
  5. d'Hemecourt, 1998, Sodium carboxymethyl cellulose aqueous-based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers, Wounds, 10, 69
  6. Driver, 2006, A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non-healing diabetic foot ulcers, Diabetes, 55, A25
  7. Driver, 2006, A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers, Ostomy/Wound Management, 52, 68
  8. Fernández-Montequin, 2007, Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation, International Wound Journal, 4, 333, 10.1111/j.1742-481X.2007.00344.x · DOI
  9. Fernández-Montequín, 2009, Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure, International Wound Journal, 6, 67, 10.1111/j.1742-481X.2008.00561.x · DOI
  10. Fernández-Montequín, 2009, Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study, International Wound Journal, 6, 432, 10.1111/j.1742-481X.2009.00641.x · DOI
  11. Hanft, 2008, Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers, Journal of Wound Care, 17, 30-2, 34-7, 10.12968/jowc.2008.17.1.27917 · DOI · Paper page
  12. Kwon, 2006, Results of a phase I, randomized, double-blind, placebo-controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers, Wound Management, 54, 102
  13. Hardikar, 2005, Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double-blind, placebo-controlled study in India, Wounds, 17, 141
  14. Holloway, 1993, A randomised controlled dose response trial of activated platelet supernatant, topical CT-102 in chronic, non healing diabetic wounds, Wounds, 5, 198–206
  15. Jaiswal, 2010, Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers, Indian Journal of Surgery, 72, 31, 10.1007/s12262-010-0005-8 · DOI
  16. Kakagia, 2007, Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial, Journal of Diabetes and its Complications, 21, 387, 10.1016/j.jdiacomp.2007.03.006 · DOI
  17. Landsman, 2010, Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis, Journal of the American Podiatric Medical Association, 100, 155, 10.7547/1000155 · DOI
  18. Parish, 2009, Diabetic foot ulcers: a randomized multicenter study comparing a moisture-controlling dressing with a topical growth factor, Journal of the American Academy of Dermatology, 60, AB202
  19. Lyons, 2007, Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study, American Journal of Surgery, 193, 49, 10.1016/j.amjsurg.2006.07.010 · DOI
  20. Niezgoda, 2005, Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers, Advances in Skin and Wound Care, 18, 258, 10.1097/00129334-200506000-00012 · DOI · Paper page
  21. Richard, 1995, Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double-blind, placebo-controlled study, Diabetes Care, 18, 64, 10.2337/diacare.18.1.64 · DOI · Paper page
  22. Robson, 2002, Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose-ranging trial, Journal of Applied Research, 2, 133
  23. Saldalamacchia, 2004, A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers, Nutrition Metabolism and Cardiovascular Diseases, 14, 395, 10.1016/S0939-4753(04)80029-2 · doi:10.1016/s0939-4753(04)80029-2
  24. Saldalamacchia, 2004, Use of autologous platelet gel for the treatment of diabetic foot ulcers, Giornale Italiano di Diabetologia e Metabolismo, 24, 103
  25. Steed, 1992, Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT-102 activated platelet supernatant, topical versus placebo, Diabetes Care, 15, 1598–604, 10.2337/diacare.15.11.1598 · DOI · Paper page
  26. Steed, 2006, Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers, Plastic and Reconstructive Surgery, 117 (Suppl7), 143, 10.1097/01.prs.0000222526.21512.4c · DOI · Paper page
  27. Steed, 1995, Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers, Journal of Vascular Surgery, 21, 71, 10.1016/S0741-5214(95)70245-8 · DOI · Paper page
  28. Steed, 1995, Promotion and acceleration of diabetic ulcer healing by arginine glycine-aspartic acid (RGD) peptide matrix, Diabetes Care, 18, 39–46, 10.2337/diacare.18.1.39 · DOI
  29. Steed, 1996, Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets, Wound Repair and Regeneration, 4, 230, 10.1046/j.1524-475X.1996.40210.x · doi:10.1046/j.1524-475x.1996.40210.x
  30. Tan, 2008, Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients, Journal of Health Science, 54, 432, 10.1248/jhs.54.432 · DOI
  31. Tsang, 2003, Human epidermal growth factor enhances healing of diabetic foot ulcers, Diabetes Care, 26, 1856, 10.2337/diacare.26.6.1856 · DOI · Paper page
  32. Uchi, 2009, Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer, European Journal of Dermatology, 19, 461, 10.1684/ejd.2009.0750 · DOI · Paper page
  33. Viswanathan, 2006, A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D 150) in healing diabetic foot ulcers, Wounds, 18, 186
  34. Wieman, 1998, Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study, Diabetes Care, 21, 822, 10.2337/diacare.21.5.822 · DOI · Paper page
  35. Acosta, 2006, Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds, International Wound Journal, 3, 232, 10.1111/j.1742-481X.2006.00237.x · DOI
  36. Embil, 2000, Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy, Wound Repair and Regeneration, 8, 162, 10.1046/j.1524-475x.2000.00162.x · DOI · Paper page
  37. Hong, 2006, Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers, Annals of Plastic Surgery, 56, 394, 10.1097/01.sap.0000198731.12407.0c · DOI · Paper page
  38. Miller, 1999, Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers, The Journal of Foot and Ankle Surgery, 38, 227, 10.1016/S1067-2516(99)80058-1 · DOI
  39. Mohan, 2007, Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers, Diabetes Research and Clinical Practice, 78, 405, 10.1016/j.diabres.2007.06.004 · DOI
  40. Saad Setta, 2011, Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study, International Wound Journal, 8, 307, 10.1111/j.1742-481X.2011.00797.x · DOI · Paper page
  41. Tuyet, 2009, The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results, International Wound Journal, 6, 159, 10.1111/j.1742-481X.2009.00594.x · doi:10.1111/j.1742-481x.2009.00594.x
  42. Yera-Alos, 2013, Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers, BMC Pharmacology and Toxicology, 14, 44, 10.1186/2050-6511-14-44 · DOI
  43. Gomez-Villa, 2014, Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial, Wound Repair and Regeneration, 22, 497, 10.1111/wrr.12187 · DOI
  44. Morimoto, 2013 Part A, Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers, Tissue engineering, 19, 1931, 10.1089/ten.tea.2012.0634 · DOI
  45. Singla, 2014, Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's Grade 1 and 2 diabetic foot ulcers: Comparative analysis of 50 patients, Journal of Natural Science, Biology and Medicine, 5, 273, 10.4103/0976-9668.136160 · doi:10.4103/0976-9668.136160
  46. Young, 1992, The treatment of diabetic neuropathic foot ulcers with biosynthetic platelet derived growth factor, Diabetic Medicine, S42
  47. Abbott, 2002, The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort, Diabetes Medicine, 19, 377, 10.1046/j.1464-5491.2002.00698.x · DOI · Paper page
  48. Albert, 2002, Cost-effective management of recalcitrant diabetic foot ulcers, Clinics in Podiatric Medicine and Surgery, 19, 483, 10.1016/S0891-8422(02)00018-6 · doi:10.1016/s0891-8422(02)00018-6
  49. Ali S Fareed A Humail S Basit A Ahmedani M Fawwad A The personal cost of diabetic foot disease in the developing world - a study from Pakistan Diabetic Medicine 2008 1231 3 · DOI
  50. Amery, 2005, Growth factors and the management of the diabetic foot, Diabetic Medicine, 22 Suppl 1, 12, 10.1111/j.1464-5491.2005.1531f.x · DOI
  51. Andersen, 2004, Technology evaluation: rh lactoferrin, Agennix, Current Opinion in Molecular Therapeutics, 6, 344
  52. Armstrong, 2008, Quality of life in healing diabetic wounds: does the end justify the means?, Journal of Foot and Ankle Surgery, 47, 278, 10.1053/j.jfas.2008.02.015 · DOI
  53. Ashry, 1998, Cost of diabetes-related amputations in minorities, The Journal of Foot and Ankle Surgery, 37, 186, 10.1016/S1067-2516(98)80108-7 · DOI
  54. Bakker, 2012, The development of global consensus guidelines on the management and prevention of the diabetic foot 2011, Diabetes/Metabolism Research and Reviews, 28, 116, 10.1002/dmrr.2254 · DOI
  55. Bakker, 2012, Practical guidelines on the management and prevention of the diabetic foot 2011, Diabetes/Metabolism Research and Reviews, 28, 225, 10.1002/dmrr.2253 · DOI · Paper page
  56. Barrientos, 2008, Growth factors and cytokines in wound healing, Wound Repair and Regeneration, 16, 585, 10.1111/j.1524-475X.2008.00410.x · DOI · Paper page
  57. Bartus, 2004, Reducing the incidence of foot ulceration and amputation in diabetes, Current Diabetes Reports, 4, 413, 10.1007/s11892-004-0049-x · DOI
  58. Basch, 2012, Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective, JAMA, 307, 1636, 10.1001/jama.2012.466 · DOI · Paper page
  59. Beckert, 2006, A new wound-based severity score for diabetic foot ulcers: a prospective analysis of 1,000 patients, Diabetes Care, 29, 988, 10.2337/dc05-2431 · doi:10.2337/dc05-2431
  60. Bennett, 2003, Growth factors in the treatment of diabetic foot ulcers, The British Journal of Surgery, 90, 133, 10.1002/bjs.4019 · DOI · Paper page
  61. Boulton, 2005, The global burden of diabetic foot disease, Lancet, 366, 1719, 10.1016/S0140-6736(05)67698-2 · DOI · Paper page
  62. Boulton, 2008, The diabetic foot: grand overview, epidemiology and pathogenesis, Diabetes/Metabolism Research and Reviews, 24 (Suppl 1), 3, 10.1002/dmrr.833 · DOI · Paper page
  63. Boutoille, 2008, Quality of life with diabetes-associated foot complications: comparison between lower-limb amputation and chronic foot ulceration, Foot and Ankle International, 29, 1074, 10.3113/FAI.2008.1074 · DOI
  64. Buchberger, 2010, The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers, GMS Health Technology Assessment, 6, Doc12
  65. Buchmayer, 2011, Actovegin(R): a biological drug for more than 5 decades, Wiener Medizinische Wochenschrift, 161, 80, 10.1007/s10354-011-0865-y · doi:10.1007/s10354-011-0865-y
  66. Chao, 2009, Microvascular dysfunction in diabetic foot disease and ulceration, Diabetes/Metabolism Research and Reviews, 25, 604, 10.1002/dmrr.1004 · DOI · Paper page
  67. Clarke, 2007, Standardising outcomes for clinical trials and systematic reviews, Trials, 8, 39, 10.1186/1745-6215-8-39 · DOI · Paper page
  68. Cruciani, 2009, Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006810 · doi:10.1002/14651858.cd006810
  69. Enoch, 2008, Basic science of wound healing, Surgery, 26, 31
  70. Figueroa-Romero, 2008, Mechanisms of disease: the oxidative stress theory of diabetic neuropathy, Reviews in Endocrine & Metabolic Disorders, 9, 301, 10.1007/s11154-008-9104-2 · DOI · Paper page
  71. Foster, 2009, Platelet-rich plasma: from basic science to clinical applications, The American Journal of Sports Medicine, 37, 2259, 10.1177/0363546509349921 · DOI · Paper page
  72. Girod, 2003, An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients, Diabetes and Metabolism, 29, 269, 10.1016/S1262-3636(07)70036-8 · DOI
  73. Goodridge, 2006, Quality of life of adults with unhealed and healed diabetic foot ulcers, Foot and Ankle International, 27, 274, 10.1177/107110070602700408 · DOI
  74. Grazul-Bilska, 2003, Wound healing: the role of growth factors, Drugs of Today, 39, 787, 10.1358/dot.2003.39.10.799472 · DOI · Paper page
  75. Guyatt, 2011, GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology, Journal of Clinical Epidemiology, 64, 380, 10.1016/j.jclinepi.2010.09.011 · DOI · Paper page
  76. Guyatt, 2011, GRADE guidelines: 7. Rating the quality of evidence - inconsistency, Journal of Clinical Epidemiology, 64, 1294, 10.1016/j.jclinepi.2011.03.017 · DOI · Paper page
  77. Guyatt, 2011, GRADE guidelines: 8. Rating the quality of evidence - indirectness, Journal of Clinical Epidemiology, 64, 1303, 10.1016/j.jclinepi.2011.04.014 · DOI · Paper page
  78. Guyatt, 2013, GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes, Journal of Clinical Epidemiology, 66, 151, 10.1016/j.jclinepi.2012.01.006 · DOI · Paper page
  79. Habib, 2010, Cost-effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh, Journal of Diabetes and its Complications, 24, 259, 10.1016/j.jdiacomp.2008.12.005 · DOI
  80. Herber, 2007, A systematic review on the impact of leg ulceration on patients' quality of life, Health and Quality of Life Outcomes, 25, 44, 10.1186/1477-7525-5-44 · DOI · Paper page
  81. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  82. Hinchliffe, 2008, A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes, Diabetes/Metabolism Research and Reviews, 24, 119–44
  83. Humphrey, 1996, Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention - a 12-year follow-up study in Nauru, Diabetes Care, 19, 710, 10.2337/diacare.19.7.710 · doi:10.2337/diacare.19.7.710
  84. International Conference on Harmonisation Expert Working Group, 1997, International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines, 1
  85. Ince, 2007, The association between baseline characteristics and the outcome of foot lesions in a UK population with diabetes, Diabetic Medicine, 24, 977, 10.1111/j.1464-5491.2007.02189.x · DOI
  86. Ince, 2008, Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents, Diabetes Care, 31, 964, 10.2337/dc07-2367 · DOI · Paper page
  87. Ioannidis, 2004, Better reporting of harms in randomized trials: an extension of the CONSORT statement, Annals of Internal Medicine, 141, 781, 10.7326/0003-4819-141-10-200411160-00009 · DOI · Paper page
  88. Ioannidis, 2010, Meta-research: the art of getting it wrong, Research Synthesis Methods, 1, 169, 10.1002/jrsm.19 · DOI · Paper page
  89. Iversen, 2008, History of and factors associated with diabetic foot ulcers in Norway: the Nord-Trøndelag Health Study, Scandinavian Journal of Public Health, 36, 62, 10.1177/1403494807085314 · DOI
  90. Izumi, 2009, Mortality of first-time amputees in diabetics: a 10-year observation, Diabetes Research and Clinical Practice, 83, 126, 10.1016/j.diabres.2008.09.005 · DOI
  91. Jeffcoate, 2003, Diabetic Foot Ulcers, Lancet, 361, 1545, 10.1016/S0140-6736(03)13169-8 · DOI · Paper page
  92. Jeffcoate, 2004, Amputation as a marker of the quality of foot care in diabetes, Diabetologia, 47, 2051, 10.1007/s00125-004-1584-3 · DOI · Paper page
  93. Jeffcoate, 2005, The incidence of amputation in diabetes, Acta Chirurgica Belgica, 105, 140, 10.1080/00015458.2005.11679687 · doi:10.1080/00015458.2005.11679687
  94. Kanade, 2007, Re-amputation occurrence in the diabetic population in South Wales, UK, International Wound Journal, 4, 344, 10.1111/j.1742-481X.2007.00313.x · doi:10.1111/j.1742-481x.2007.00313.x
  95. Kinmond, 2003, 'Loss of self': a psychosocial study of the quality of life of adults with diabetic foot ulceration, Journal of Tisssue Viability, 13, 6-8, 10, 12, 10.1016/S0965-206X(03)80025-6 · DOI
  96. Köveker, 2000, Growth factors in clinical practice, International Journal of Clinical Practice, 54, 590, 10.1111/j.1742-1241.2000.tb10933.x · DOI
  97. Lacci, 2010, Platelet-rich plasma: support for its use in wound healing, The Yale Journal of Biology and Medicine, 83, 1
  98. Lantis, 2009, Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer, Advances in Skin and Wound Care, 22, 167, 10.1097/01.ASW.0000305466.25177.a8 · DOI
  99. Lavery, 1996, Classification of diabetic foot wounds, The Journal of Foot and Ankle Surgery, 35, 528, 10.1016/S1067-2516(96)80125-6 · DOI · Paper page
  100. Lavery, 2008, Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot, Diabetes Care, 31, 154, 10.2337/dc07-1302 · DOI · Paper page
  101. Lavery, 2009, Risk factors for developing osteomyelitis in patients with diabetic foot wounds, Diabetes Research and Clinical Practice, 83, 347, 10.1016/j.diabres.2008.11.030 · DOI · Paper page
  102. Lee, 1993, Lower-extremity amputation. Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study, Diabetes, 42, 876, 10.2337/diab.42.6.876 · doi:10.2337/diab.42.6.876
  103. Lefebvre C Manheimer E Glanville J on behalf of the Cochrane Information Retrieval Methods Group Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  104. Lehto, 1996, Risk factors predicting lower extremity amputations in patients with NIDDM, Diabetes Care, 19, 607, 10.2337/diacare.19.6.607 · DOI · Paper page
  105. Leymarie, 2005, Factors associated with diabetic patients at high risk for foot ulceration, Diabetes and Metabolism, 31, 603, 10.1016/S1262-3636(07)70238-0 · DOI
  106. Lipsky, 2004, Diagnosis and treatment of diabetic foot infections, Clinical Infectious Disease, 39, 885, 10.1086/424846 · DOI · Paper page
  107. Meatherall, 2005, Disability and quality of life in Canadian aboriginal and non-aboriginal diabetic lower-extremity amputees, Archives of Physical Medicine and Rehabilitation, 86, 1594, 10.1016/j.apmr.2004.11.026 · DOI
  108. Milman, 2001, Diabetic foot: evaluation of evolution and hospital cost of hospitalized patients in Conjunto Hospitalar de Sorocaba, Arquivos Brasileiros de Endocrinologia e Metabologia, 45, 447, 10.1590/S0004-27302001000500007 · doi:10.1590/s0004-27302001000500007
  109. Moss, 1996, Long-term incidence of lower-extremity amputations in a diabetic population, Archives of Family Medicine, 5, 391, 10.1001/archfami.5.7.391 · DOI
  110. Nabuurs-Franssen, 2005, Health-related quality of life of diabetic foot ulcer patients and their caregivers, Diabetologia, 48, 1906, 10.1007/s00125-005-1856-6 · DOI · Paper page
  111. Nelson, 1988, Lower-extremity amputations in NIDDM. 12-year follow-up study in Pima Indians, Diabetes Care, 11, 8, 10.2337/diacare.11.1.8 · DOI · Paper page
  112. O'Meara, 2000, Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration, Health Technology Assessment, 4, 1
  113. Oyibo, 2001, The effects of ulcer size and site, patient’s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers, Diabetic Medicine, 18, 133, 10.1046/j.1464-5491.2001.00422.x · DOI · Paper page
  114. Papanas, 2007, Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?, The International Journal of Lower Extremity Wounds, 6, 37, 10.1177/1534734606298416 · DOI
  115. Papanas, 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers, Clinical Interventions in Aging, 3, 233, 10.2147/CIA.S1106 · DOI
  116. Papanas, 2010, Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers, Drug Safety, 33, 455, 10.2165/11534570-000000000-00000 · DOI
  117. Porta, 2008, A Dictionary of Epidemiology
  118. Pradhan, 2009, Inflammation and neuropeptides: the connection in diabetic wound healing, Expert Reviews in Molecular Medicine, 11, e2, 10.1017/S1462399409000945 · DOI · Paper page
  119. Price, 2004, The diabetic foot: quality of life, Clinical Infectious Diseases, 39, 129, 10.1086/383274 · DOI
  120. Quattrini, 2008, Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy, Diabetes Care, 31, 140, 10.2337/dc07-1556 · DOI
  121. Ramsey, 1999, Incidence, outcomes, and cost of foot ulcers in patients with diabetes, Diabetes Care, 22, 382, 10.2337/diacare.22.3.382 · DOI · Paper page
  122. Rathur, 2007, The diabetic foot, Clinics in Dermatology, 25, 109, 10.1016/j.clindermatol.2006.09.015 · DOI
  123. Redekop, 2004, Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments, Diabetes and Metabolism, 30, 549, 10.1016/S1262-3636(07)70154-4 · DOI
  124. Ribu, 2008, A longitudinal study of patients with diabetes and foot ulcers and their health-related quality of life: wound healing and quality-of-life changes, Journal of Diabetes Complications, 22, 400, 10.1016/j.jdiacomp.2007.06.006 · DOI
  125. Richard, 2008, Epidemiology of diabetic foot problems, La Revue Médicine Interne, 29, 222, 10.1016/S0248-8663(08)73949-3 · DOI
  126. Rith-Najarian, 1992, Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria, Diabetes Care, 15, 1386, 10.2337/diacare.15.10.1386 · DOI · Paper page
  127. Rozman, 2007, Use of platelet growth factors in treating wounds and soft-tissue injuries, Acta Dermatovenerologica Alpina, Panonica, et Adriatica, 16, 156
  128. Schaper, 2004, Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies, Diabetes/Metabolism Research and Reviews, 20, 90, 10.1002/dmrr.464 · DOI · Paper page
  129. Schaper, 2012, Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system, Diabetologia, 55, 1869, 10.1007/s00125-012-2588-z · DOI
  130. Schaper, 2012, Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot, Diabetes/Metabolism Research and Reviews, 28, 218, 10.1002/dmrr.2255 · DOI · Paper page
  131. Selby, 2012, The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda, JAMA, 307, 1583, 10.1001/jama.2012.500 · DOI · Paper page
  132. Sheehan, 2006, Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial, Plastic and Reconstructive Surgery, 117(7 Suppl), 239, 10.1097/01.prs.0000222891.74489.33 · DOI · Paper page
  133. Sibbald, 2008, The biology of chronic foot ulcers in persons with diabetes, Diabetes/Metabolism Research and Reviews, 24, 25, 10.1002/dmrr.847 · DOI · Paper page
  134. Siriwardana, 2007, The cost of diabetic foot conditions, The Ceylon Medical Journal, 52, 89, 10.4038/cmj.v52i3.966 · doi:10.4038/cmj.v52i3.966
  135. Skoutas, 2009, Risk factors for ipsilateral reamputation in patients with diabetic foot lesions, The International Journal of Lower Extremity Wounds, 8, 69, 10.1177/1534734609334808 · DOI
  136. Smith, 2004, The cost of managing diabetic foot ulceration in an Irish hospital, Irish Journal of Medical Science, 173, 89, 10.1007/BF02914564 · DOI
  137. Smyth, 2009, Platelet functions beyond hemostasis, Journal of Thrombosis and Haemotasis, 7, 1759, 10.1111/j.1538-7836.2009.03586.x · DOI · Paper page
  138. Valensi, 2005, Quality of life and clinical correlates in patients with diabetic foot ulcers, Diabetes and Metabolism, 31, 263, 10.1016/S1262-3636(07)70193-3 · DOI
  139. Acker, 2000, Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium, Diabetes Research and Clinical Practice, 50, 87, 10.1016/S0168-8227(00)00157-1 · DOI
  140. Houtum, 2008, Amputations and ulceration; pitfalls in assessing incidence, Diabetes/Metabolism Research and Reviews, 24, 14, 10.1002/dmrr.826 · doi:10.1002/dmrr.826
  141. Veves, 1992, The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study, Diabetologia, 35, 660, 10.1007/BF00400259 · DOI · Paper page
  142. Viswanathan, 2005, Profile of diabetic foot complications and its associated complications - a multicentric study from India, The Journal of Association Physicians of India, 53, 933
  143. Viswanathan, 2006, A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-DTM 150) in healing diabetic foot ulcers, Wounds, 18, 186
  144. Wagner, 1981, The dysvascular foot: a system of diagnosis and treatment, Foot and Ankle International, 2, 64, 10.1177/107110078100200202 · DOI · Paper page
  145. Weinberg, 2003, The therapeutic potential of lactoferrin, Expert Opinion on Investigational Drugs, 12, 841, 10.1517/13543784.12.5.841 · DOI
  146. Wieman, 1998, Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group, American Journal of Surgery, 176, 74S, 10.1016/S0002-9610(98)00185-8 · DOI · Paper page
  147. Willrich, 2005, Health related quality of life, cognitive function, and depression in diabetic patients with foot ulcer or amputation. A preliminary study, Foot and Ankle International, 26, 128, 10.1177/107110070502600203 · DOI
  148. Winkley, 2007, Risk factors associated with adverse outcomes in a population-based prospective cohort study of people with their first diabetic foot ulcer, Journal of Diabetes and its Complications, 21, 341, 10.1016/j.jdiacomp.2007.09.004 · DOI
  149. Younes, 2004, Diabetic heel ulcers: a major risk factor for lower extremity amputation, Ostomy/Wound Management, 50, 50
  150. Young, 1994, The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study, Diabetes Care, 17, 557, 10.2337/diacare.17.6.557 · DOI · Paper page
  151. Ziyadeh, 2011, A matched cohort study of the risk of cancer in users of becaplermin, Advances in Skin and Wound Care, 24, 31, 10.1097/01.ASW.0000392922.30229.b3 · DOI

Cited by

See all 192

Metadata

Authors
Martí-Carvajal, A. J., Gluud, C., Nicola, S., Simancas-Racines, D., Reveiz, L., Oliva, P., & Cedeño-Taborda, J.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2015-10-28
Volume
2015
Issue
10
Pages
CD008548-CD008548
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2117595314
Cited by
192
References
19
FWCI
11.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Growth factors for treating diabetic foot ulcers. https://app.cochat.ai/papers/10.1002/14651858.cd008548.pub2
The paper
Martí-Carvajal, A. J., Gluud, C., Nicola, S., Simancas-Racines, D., Reveiz, L., Oliva, P., & Cedeño-Taborda, J. (2015). Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008548.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.